{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-092967","form_type":"8-K","ticker":"KYNB","cik":"0000921299","company_name":"KYNTRA BIO, INC.","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.367541+00:00","generated_at":"2026-05-31T12:02:53.694469+00:00","sec_items":["2.05"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"FibroGen cuts 75% of U.S. workforce (127 employees); charges $16-18M","bullets":["Workforce reduction of ~75% (127 U.S. employees) effective Aug 2, 2024.","Estimated non-recurring charges of $16-18M for severance, payroll, benefits.","Majority of charges expected in H2 2024; cash payments substantially complete by Q1 2025.","Restructuring follows negative pamrevlumab clinical trial data announced earlier that week.","Potential position eliminations subject to legal requirements; process may extend beyond Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-092967","json":"https://secwatch.observer/filing/0000950170-24-092967.json","markdown":"https://secwatch.observer/filing/0000950170-24-092967.md","text":"https://secwatch.observer/filing/0000950170-24-092967.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921299/000095017024092967/0000950170-24-092967-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921299/000095017024092967/fgen-20240802.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:02:53.694469+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"31af42f5cf7c4defce76726fdbf28eca327d17cb","claim":"KYNTRA BIO, INC. announced a restructuring with charges of $16-18 million affecting U.S. workforce (approximately 75% with 127 U.S. employees).","evidence_excerpt":"in the progress we have made, and continue to make, in science and the biotechnology industry. The Company estimates that it will incur non-recurring charges in the range of $16-18 million in connection with the Plan, primarily consisting of severance payments, notice pay, accrued vacation, payroll tax and employee benefits contributions. The Company","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/921299/000095017024092967/0000950170-24-092967-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"$16-18 million"},{"label":"Affected area","value":"U.S. workforce"},{"label":"Headcount","value":"approximately 75% with 127 U.S. employees"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}